Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982176 | 1.00 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL28982175 | 1.00 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL30385583 | 1.00 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL5631124 | 0.96 | KMT2A (0.47) | MDM2MDM4TP53KMT2A | |
| SCHEMBL5631131 | 0.96 | KMT2A (0.47) | MDM2MDM4TP53KMT2A | |
| SCHEMBL30385844 | 0.95 | KMT2A (0.46) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL30385972 | 0.94 | MDM2 (0.45) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL23080684 | 0.92 | MDM2 (0.43) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL12757436 | 0.91 | MDM2 (0.54) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL4600320 | 0.91 | MDM2 (0.54) | MDM2MDM4TP53CASP3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | MDM2 2262/4885MDM4 1323/4885TP53 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.